Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy

20260 citationsJournal Article

Authors

Joseph W. Rossano · Children's Hospital of Philadelphia

Charles Canter · Washington University in St. Louis

Cordula M. Wolf · Deutsches Herzzentrum München

Andrew L. Papez · Phoenix Children's Hospital

Marta Gambra · Hospital Universitario La Paz

Randall M. Bryant · Atrium Medical Cente

Juan Alejos

Abstract

Among adolescent patients with obstructive hypertrophic cardiomyopathy, the reduction in left ventricular outflow tract obstruction was significantly greater with mavacamten than with placebo over a 28-week period. (Funded by Bristol Myers Squibb; SCOUT-HCM ClinicalTrials.gov number, NCT06253221.).

Topics & Keywords

Cardiomyopathy and Myosin Studies Cardiovascular Effects of Exercise Pericarditis and Cardiac Tamponade

Publication Details

Published in: New England Journal of Medicine

DOI: 10.1056/nejmoa2601103

Field-Weighted Citation Impact: 0.00

Command Palette

Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy

Authors

Abstract

Topics & Keywords

Publication Details